Interleukin-1β Promoter polymorphism enhances the risk of sleep disturbance in Alzheimer's disease

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Yin, You ^a   Liu, Yan ^b   Pan, Xiao ^a   Chen, Rui ^a   Li, Peng ^a   Wu, Hui Juan ^a   Zhao, Zheng Qing ^a   Li, Yan Peng ^a   Huang, Liu Qing ^a   Zhuang, Jian Hua ^a   Zhao, Zhong Xin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; GENOMIC DNA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; IL1B PROTEIN, HUMAN; LIPOPOLYSACCHARIDE;

AGED; ALLELE; ALZHEIMER DISEASE; APOEEPSILON4 GENE; ARTICLE; CONTROLLED STUDY; EPWORTH SLEEPINESS SCALE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IL 1BETA 31 GENE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYSOMNOGRAPHY; PROMOTER REGION; PROTEIN BLOOD LEVEL; REM SLEEP; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; SLEEP TIME; SLEEP WAKING CYCLE; VERY ELDERLY; BIOSYNTHESIS; CASE CONTROL STUDY; CELL CULTURE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; SECRETION (PROCESS);

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SLEEP WAKE DISORDERS;

EID: 84961141671     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149945     Document Type: Article

References (47)

1. Malkki H. Alzheimer disease: Sleep alleviates AD-related neuropathological processes. Nat Rev Neurol. 2013; 9:657. doi: 10.1038/nrneurol.2013.230
2. Eun Y, Jeon BS. Clinical Implication of REM Sleep Behavior Disorder in Parkinson's Disease. J Parkinsons Dis. 2014; 4: 237-244. doi: 10.3233/JPD-130293
3. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007; 27:42-47.
4. McCurry SM, Logsdon RG, Teri L, Gibbons LE, Kukull WA, Bowen JD, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatry Neurol. 1999; 12:53-59.
5. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367:795-804. doi: 10.1056/NEJMoa1202753
6. Chen R, Yin Y, Zhao Z, Huang L, Huang S, Zhuang J, et al. Elevation of serum TNF-Alpha levels in mild and moderate Alzheimer patients with daytime sleepiness. J Neuroimmunol. 2012; 244:97-102. doi: 10.1016/j.jneuroim.2011.12.015
7. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21:383-421.
8. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. J Neuroimmunol. 2008; 193:183-187.
9. Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol. 2002; 72:233-238.
10. Yang L, Lu R, Jiang L, Liu Z, Peng Y. Expression and genetic analysis of tumor necrosis factor-Alpha (TNF-Alpha) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population. Brain Res. 2009; 1247:178-181. doi: 10.1016/j.brainres.2008.10.019
11. Krueger JM, Walter J, Dinarello CA, Wolff SM, Chedid L. Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol. 1984; 246:R994-R999.
12. Fang J, Wang Y, Krueger JM. Effects of interleukin-1 beta on sleep are mediated by the type I receptor. Am J Physiol. 1998; 274:R655-R660.
13. Opp MR. Cytokines and sleep. Sleep Med Rev. 2005; 9:355-364.
14. Jewett KA, Krueger JM. Humoral sleep regulation; interleukin-1 and tumor necrosis factor. Vitam Horm. 2012; 89:241-257. doi: 10.1016/B978-0-12-394623-2.00013-5
15. Basu A, Krady JK, Levison SW. Interleukin-1: A master regulator of neuroinflammation. J Neurosci Res. 2004; 78:151-156.
16. Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, et al. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: A systematic review and meta-Analysis. Brain Res Rev. 2008; 59:155-163. doi: 10.1016/j.brainresrev.2008.07.003
17. Um JY, Moon KS, Lee KM, Kim HM. Interleukin-1 gene cluster polymorphisms in cerebral infarction. Cytokine. 2003; 23:41-46.
18. Wen AQ, Jiang JX, Zhu PF, Feng K. [Linkage disequilibrium analysis of-31,-511,-1470 single nucleotide polymorphisms in the promoter of IL-1 beta in Chongqing population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004; 21:412-414.
19. Wen AQ, Wang J, Feng K, Zhu PF, Wang ZG, Jiang JX. Effects of haplotypes in the interleukin 1beta promoter on lipopolysaccharide-induced interleukin 1beta expression. Shock. 2006; 26:25-30.
20. Yucesoy B, Peila R, White LR, Wu KM, Johnson VJ, Kashon ML, et al. Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: The Honolulu-Asia Aging Study. Neurobiol Aging. 2006; 27:211-217.
21. Grimaldi LM, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, et al. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol. 2000; 47:361-365.
22. Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, et al. Gene polymorphism affecting alpha1-Antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol. 2000; 48:388-391.
23. Wang WF, Liao YC, Wu SL, Tsai FJ, Lee CC, Hua CS. Association of interleukin-I beta and receptor antagonist gene polymorphisms with late onset Alzheimer's disease in Taiwan Chinese. Eur J Neurol. 2005; 12:609-613.
24. Payao SL, Goncalves GM, de Labio RW, Horiguchi L, Mizumoto I, Rasmussen LT, et al. Association of interleukin 1beta polymorphisms and haplotypes with Alzheimer's disease. J Neuroimmunol. 2012; 247:59-62. doi: 10.1016/j.jneuroim.2012.03.012
25. Delgado-Lista J, Garcia-Rios A, Perez-Martinez P, Solivera J, Yubero-Serrano EM, Fuentes F, et al. Interleukin 1B variant-1473G/C (rs1143623) influences triglyceride and interleukin 6 metabolism. J Clin Endocrinol Metab. 2011; 96:E816-E820. doi: 10.1210/jc.2010-2455
26. Pericak-Vance MA, Bebout JL, Gaskell PC Jr., Yamaoka LH, Hung WY, Alberts MJ, et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991; 48:1034-1050.
27. Dursun E, Gezen-Ak D, Eker E, Ertan T, Engin F, Hanagasi H, et al. Presenilin-1 gene intronic polymorphism and late-onset Alzheimer's disease. J Geriatr Psychiatry Neurol. 2008; 21:268-273. doi: 10. 1177/0891988708324941
28. Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry. 2010; 15:756-766. doi: 10.1038/mp.2008.141
29. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939-944.
30. Kundermann B, Thum A, Rocamora R, Haag A, Krieg JC, Hemmeter U. Comparison of polysomnographic variables and their relationship to cognitive impairment in patients with Alzheimer's disease and frontotemporal dementia. J Psychiatr Res. 2011; 45:1585-1592. doi: 10.1016/j.jpsychires.2011. 07.008
31. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human sleep subjects. Washington DC, US: Government Printing Office; 1968
32. Emery A. Methodology in Medical Genetics: An Introduction to Statistical Methods: Edinburgh, UK: Longman Group Ltd; 1986.
33. Benke KS, Carlson MC, Doan BQ, Walston JD, Xue QL, Reiner AP, et al. The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study. Exp Gerontol. 2011; 46:1010-1019. doi: 10.1016/j.exger.2011.09.005
34. Henderson ST, Poirier J. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study. BMC Med Genet. 2011; 12:137. doi: 10.1186/1471-2350-12-137
35. Ma SL, Tang NL, Lam LC, Chiu HF. Lack of association of the interleukin-1beta gene polymorphism with Alzheimer's disease in a Chinese population. Dement Geriatr Cogn Disord. 2003; 16:265-268.
36. Klimkowicz-Mrowiec A, Marona M, Wolkow P, Maruszak A, Styczynska M, Barcikowska M, et al. Interleukin-1 gene-511 CT polymorphism and the risk of Alzheimer's disease in a Polish population. Dement Geriatr Cogn Disord. 2009; 28:461-464. doi: 10.1159/000259460
37. Minster RL, DeKosky ST, Ganguli M, Belle S, Kamboh MI. Genetic association studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer's disease. Ann Neurol. 2000; 48:817-819.
38. Green EK, Harris JM, Lemmon H, Lambert JC, Chartier-Harlin MC, St Clair D, et al. Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology. 2002; 58:1566-1568.
39. Hedley R, Hallmayer J, Groth DM, Brooks WS, Gandy SE, Martins RN. Association of interleukin-1 polymorphisms with Alzheimer's disease in Australia. Ann Neurol. 2002; 51:795-797.
40. Capurso C, Solfrizzi V, D'Introno A, Colacicco AM, Capurso SA, Capurso A, et al. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe. Exp Gerontol. 2004; 39:1567-1573.
41. Wen AQ, Gu W, Wang J, Feng K, Qin L, Ying C, et al. Clinical relevance of IL-1beta promoter polymorphisms (-1470,-511, and-31) in patients with major trauma. Shock. 2010; 33:576-582. doi: 10.1097/SHK.0b013e3181cc0a8e
42. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000; 1:507-537.
43. Laskowitz D, Lee D, Schmechel D, Staats H. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res. 2000; 41:613-620.
44. De Simoni M, Del Bo R, De Luigi A, Simard S, Forloni G. Central endotoxin induces different patterns of interleukin (IL)-1 beta and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology. 1995; 136:897-902.
45. Sala G, Galimberti G, Canevari C, Raggi ME, Isella V, Facheris M, et al. Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging. 2003; 24:909-914.
46. Delacourte A, Sergeant N, Champain D, Wattez A, Maurage C-A, Lebert F, et al. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 2002; 59:398-407.
47. Jiang Z, Hu P, Liu J, Wang D, Jin L, Hong C. Screening preoperative Peptide biomarkers for predicting postoperative myocardial infarction after coronary artery bypass grafting. PLoS One. 2014; 9:e100149. doi: 10.1371/journal.pone.0100149